Central Lab Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 6.51 Bn

Forecast Year, 2035

USD 15.78 Bn

CAGR, 2026 - 2035

9.26%

Report Coverage

Global

What is Central Lab Market Size?

The global central lab market size is calculated at USD 6.51 billion in 2025 and is predicted to increase from USD 7.17 billion in 2026 to approximately USD 15.78 billion by 2035, expanding at a CAGR of 9.26% from 2025 to 2034. The market is driven by an increasing number of clinical trials and rising demand for standardized and efficient laboratory testing services.

Market Highlights

• North America led the global market with the highest market share of 43.64% in 2025.
• By product type, the biomarkers services segment registered a maximum market share of 40.72% in 2025.
• By end user, the pharmaceutical companies segment captured the biggest revenue share of 46.43% in 2025.

Market Overview: Strategic Overview of the Global Central Lab Industry

The global central lab market is witnessing significant growth, driven by a growing need for standardized laboratory testing services, an increase in the number of clinical trials, and an increase in funding for pharmaceutical and technological research. By offering reliable, high-quality testing data management, biomarker analysis, and sample processing services across several study sites, central laboratories are essential to the success of clinical trials. Further driving market expansion are the rising incidence of chronic illnesses, the growing emphasis on individualized therapy, and the growing uptake of cutting-edge diagnostic technology. Furthermore, improvements in automation, digital pathology, data analytics, and clinical trial globalization as well as increased outsourcing by pharmaceutical and biotechnology firms, are boosting laboratory accuracy and efficiency, which is propelling the central lab industry's expansion.

Central laboratory is defined as a medical laboratory that serves several facilities or institutions. The definition also includes laboratories that serve only one hospital or institution but are not located onsite; these act as service providers for clinical laboratories within healthcare facilities. Other terms used to define central lab services include "corporate-type labs" and "national reference laboratory systems." This report describes different types of central lab services according to their organizational structure and management, the functions they perform and their relationships with healthcare institutions.

The main objectives of a central lab service are: to provide efficient and appropriate testing; to assure quality control and maintain continuous monitoring; to reduce costs by coordinating, controlling, and consolidating purchasing; to promote accountability for results; and to support training in hematology, clinical chemistry, serology/immunology/mycobacteriology, microbiology, virology/parasitology/mycology and molecular biology. The provision of these services involves several steps: development of technical protocols or procedures that guarantee standardization in each procedure performed in the lab; proper environmental conditions created through training, equipment and supplies; the availability of trained staff who are properly supervised by a more technically qualified person; coordination with other healthcare providers in order to ensure that specimens are collected at appropriate times of stability for analytes being tested.

Integration of Artificial Intelligence Enhancing Central Laboratory Efficiency

By enhancing data analysis, sample management, and clinical trial efficiency, AI is progressively changing the central lab market. AI-powered platforms reduce human error and speed up decision-making by enabling central laboratories to handle massive amounts of clinical and diagnostic data more quickly and accurately. To assist precision medicine projects and improve clinical trial outcomes, machine learning algorithms are being used for biomarker identification, predictive analytics, and automated interpretation of laboratory results. Furthermore, AI-driven automation increases overall operational efficiency, optimizes resource usage, and simplifies workflow management, enabling central laboratories to handle complicated and extensive clinical trials.

Market Outlook

• Market Growth Overview: The central lab market is expected to grow significantly between 2025 and 2034, driven by rising clinical trials and outsourcing, precision medicine and genetic testing, and increased R&D investment.
• Sustainability Trends: Sustainability trends involve energy efficiency and green lab certification, waste minimization and the circular economy, and data management and digitalization.
• Major Investors: Major investors in the market include Thermo Fisher Scientific Inc., Labcorp, ICON plc., IQVIA, Eurofins Scientific, and Medpace.
• Startup Economy: The startup economy is focused on specialized testing and diagnostics, data management and LIMS, and AI and automation.

Central Lab Market Trends

• Growing Adoption of Precision Medicine: The increasing focus on personalized therapies is driving demand for biomarker, genetic, and molecular testing services in central laboratories.
• Expansion of Decentralized Clinical Trials (DCTs): The rising adoption of decentralized and hybrid clinical trial models is increasing the need for efficient central laboratory support and data integration.
• Integration of Artificial Intelligence and Automation: Central laboratories are increasingly adopting AI, robotics, and automation technologies to improve workflow efficiency and reduce manual errors.
• Rising Use of Biomarker Testing: The growing use of biomarkers in drug development and clinical research is significantly boosting demand for specialized laboratory services.
• Increasing Outsourcing by Pharmaceutical and Biotechnology Companies: Drug developers are increasingly outsourcing laboratory operations to central labs to reduce costs and ensure standardized testing.
• Advancements in Genomic and Molecular Diagnostics: Technological advancements in next-generation sequencing (NGS) and molecular diagnostics are expanding service offerings in central laboratories.
• Growing Focus on Data Management and Analytics: Central laboratories are investing in advanced data analytics platforms to manage large volumes of clinical trial data efficiently.
• Expansion of Global Clinical Trials: The increasing globalization of clinical trials is driving demand for centralized testing services that ensure consistency across multiple study sites.

Central Lab Market Growth Factors

• Rising Number of Clinical Trials: The increasing volume of clinical trials worldwide is significantly driving demand for central laboratory services.
• Growing Pharmaceutical and Biotechnology R&D Investments: Rising investments in drug discovery and development activities are supporting market growth.
• Increasing Prevalence of Chronic Diseases: The growing burden of chronic diseases is accelerating the development of novel therapies, thereby boosting laboratory testing requirements.
• Rising Demand for Standardized Laboratory Testing: Central laboratories provide consistent and high-quality testing services across multiple clinical trial sites, supporting market expansion.
• Expansion of Precision Medicine Initiatives: The growing adoption of personalized medicine is increasing the need for advanced biomarkers and genetic testing services.
• Increasing Outsourcing of Laboratory Services: Pharmaceutical and biotechnology companies are increasingly outsourcing laboratory activities to improve efficiency and reduce operational costs.
• Technological Advancements in Laboratory Testing: Innovations in molecular diagnostics, genomics, and laboratory automation are enhancing testing capabilities and driving market growth.
• Growth in Emerging Markets: Expanding clinical research activities and improving healthcare infrastructure in emerging economies are creating new growth opportunities for the market.

Market Scope

Market Dynamics

Drivers

• Central Lab Increase New Product Development Efficiency & Speed

Central laboratories increase the speed at which new products come onto the market by carrying out early-stage development work such as pre-clinical testing. Central laboratories are designed with the specific requirements of the API in mind.

• Central Laboratories Reduce Manufacturing Costs

Central labs can reduce costs by removing unnecessary handling steps involved when transporting API between facilities, thus reducing reagent consumption which results in less waste.

• Central Lab Increase Manufacturing Flexibility

By decentralizing API manufacture to several central locations, companies have far greater flexibility for when they decide to bring a new product onto the market. There is no need to wait until sufficient production capacity has been installed at one site before bringing out a new product range which further reduces time to Market.

• Central Lab Lead to Improved Resource Efficienct & Product Quality

The improved resource efficiency that comes from moving manufacturing closer to markets means that companies can be more environmentally conscious by reducing carbon emissions and packaging waste. Allowing local HQ to have greater oversight of the products being made also leads to product quality being improved.

Opportunities

Central Labs Bring New Opportunities for Multinational Companies

Multinational companies with R&D centers around the world benefit from central labs because they enable them to bring new compounds onto the market more quickly by removing unnecessary steps in transport, thus leading to a huge increase in speed and efficiency. Central lab manufacturing facilities can be built relatively quickly which means that a company can begin work on a compound without having long term plans about where it will manufacture the finished product.

One of the key questions for multinational corporations is to determine which areas of their business are ripe for centralization. Now, central labs bring new opportunities to various corporations, whether it is certain industries or centralizing entire laboratories. With this concept, many companies will be able to compete with industry leaders by centralizing specific areas of their business. Central labs are particularly useful for industries that have never been centralize before. For example, centralizing R&D for new products is one of the most important issues that many corporations struggle with today. This concept can be centralization into a central lab to make sure that projects are centralize to produce the best possible product.

Segment Insights

Central Lab Market, By Product Type, 2022-2024 (USD Million)

End User Insights

The Pharmaceutical Companies Segment Dominated the Market in 2025

In 2025, the pharmaceutical companies segment accounted for the largest share of the central lab market because there are increasingly large-scale clinical studies and drug development initiatives being carried out worldwide. To guarantee standardized results, regulatory compliance, and operational efficiency, pharmaceutical companies frequently outsource laboratory testing and data management tasks to central laboratories. The segment's dominance is also being reinforced by rising investments in research and development.

The biotechnology companies segment is expected to grow at the fastest rate during the forecast period, driven by growing advancements in gene therapy, cell-based medicines, and biologics. To assist complex clinical investigations, biotech companies are increasingly collaborating with central laboratories for specialized testing, biomarker analysis, and genomic services. Growing venture capital investments in biotechnology and the expansion of precision medicine research are driving segment growth.

However, this is no longer an issue because more clinical trials are done through centralized laboratories. The centralization of data enables better coordination between the various phases of the trial so that all researchers involved know what stage participants have reached at any given time. That means there are fewer delays in processing and analysis.

Central lab also has its own advantages: It can provide access to a large number of samples and research data as well as the capability to perform complex tests such as genetic sequencing, which can show how different drugs interact with genetic material. In addition, central lab is able to run long-term studies that monitor participants over an extended period. This means that researchers can collect more detailed information for each individual participant and reduce errors and bias when analyzing data.

Pharmaceutical companies are now making use of central labs because they want to develop new products, which can be finished even faster than before. Central labs are also more efficient and cost saving for big multinational pharmaceutical companies which have their own R&D centres around the world. Manufacturing has moved out from developed countries like Japan and Germany to developing countries like China (and other countries in Asia). The following discusses why this is happening:

The motivation for this change is threefold: first, companies are no longer satisfied with the existing product range. Second, there is a strong urge to reduce time to market through product innovation. Third, outsourcing to an external provider was often required by general management due to limitations at internal R&D centers.

- Manufacturing has moved out from developed countries like Japan and Germany to developing countries like China (and other countries in Asia).

- Product innovation encourages pharmaceutical companies to move their manufacturing sites into many more locations around the globe.

- The new challenges are located near customers, have global supply chains and are economically attractive for local or regional activities of pharmaceutical companies. This means expanding upstream beyond chemical synthesis, downstream beyond final production steps to include API and drug product manufacturing, as well-as additional managerial tasks at the partner site.

Central Lab Market, By End User, 2022-2024 (USD Million)

Regional Insights

U.S. Central Lab Market Size and Growth 2026 to 2035

The U.S. central lab market size is exhibited at USD 2.37 billion in 2025 and is projected to be worth around USD 5.19 billion by 2035, growing at a CAGR of 8.15% from 2026 to 2035

What Made North America Dominant in the Market in 2025?

North America led the central lab market in 2025 because there is a large concentration of clinical trials, sophisticated healthcare infrastructure, and a well-established pharmaceutical and biotechnology business. Significant investments in research and development, robust regulatory frameworks, and the existence of top central laboratory service providers all benefit the area. Regional market leadership is further reinforced by the increasing use of cutting-edge laboratory technologies.

U.S. Market Trends

The United States was dominant in the market due to its substantial clinical trial operations, sophisticated healthcare infrastructure, and robust presence of pharmaceutical and biotechnology businesses. The nation benefits from large investments in drug development and precision medicine research, and it is home to many of the top central laboratory service providers. Additionally, the market in the U.S. is still being strengthened by widespread adoption of cutting-edge laboratory technologies.

Surging Clinical Trials & Healthcare Spending are Driving the Asia Pacific

Asia Pacific is expected to witness the fastest growth during the forecast period in the central lab market, driven by growing clinical trial activity, rising healthcare costs, and growing biotechnology and pharmaceutical industries in nations like China, India, and Japan. Global sponsors are drawn to the region by lower trial expenses, a sizable patient base, and supportive government initiatives to advance clinical research. Asia Pacific market growth is also being accelerated by expanding outsourcing operations and enhancing healthcare infrastructure.

Indian Market Trends

India is emerging as one of the fastest-growing markets for central laboratory services due to the growing pharmaceutical and biotechnology businesses, the rise in clinical trials, and the financial benefits of undertaking research. The nation's sizable patient population, developing healthcare systems, and increasing clinical research outsourcing by international pharmaceutical firms are all contributing factors to the market's expansion. The growth of central laboratory services in India is also being accelerated by encouraging government efforts and increased funding in life sciences research.

Value Chain Analysis of the Central Lab Market

• Specimen Management & Logistics (Pre-Analytical Phase)
  This critical initial stage involves supplying sample collection kits to clinical trial sites globally, managing the logistics, transportation, and tracking of patient specimens to the central lab facility.
  Key Players: Labcorp (Covance), ICON plc (ICON Central Labs), and Eurofins Scientific
• Laboratory Operations & Analysis (Analytical Phase)
  Once samples arrive, they undergo rigorous processing, testing, and analysis using advanced instrumentation and methodologies.
  Key Players: Quest Diagnostics, Labcorp, Eurofins Central Laboratory, ACM Global Central Lab, and Cerba Research
• Data Management & Reporting (Post-Analytical Phase)
  This stage focuses on managing the vast amount of data generated during analysis, ensuring data integrity, providing safety alerts, and delivering standardized, comprehensive reports to investigators and sponsors.
  Key Players: ICON plc, Medpace
• Client Services & R&D Support
  This stage involves engaging with clients, primarily pharmaceutical and biotechnology companies, throughout the drug development lifecycle.
  Key Players: Contract Research Organizations (CROs) like IQVIA (Q² Solutions), ICON plc, and Charles River Laboratories

Competitive Landscape

The central lab market has key firms, such as Labcorp, IQVIA, & ICON plc, which are offering end-to-end solutions combining central laboratory testing with clinical trial management, logistical support, and broader global networks. On the other hand, major competitors, like Medpace, Eurofins Scientific, & ACM Global Laboratories, emphasize operational agility, niche therapeutic areas & highly precise assay development.

Top Companies in the Central Lab Market & Their Offerings

• ACM Global Central Lab: A prominent provider of central lab services, ACM contributes to clinical trials globally by managing lab testing, logistics, and data for pharmaceutical and biotech clients.
• ICON: As a global contract research organization (CRO) with a dedicated central laboratory division, ICON contributes significantly by providing integrated clinical development services that span trial management and lab analysis.
• PPD: Now part of Thermo Fisher Scientific, PPD provides comprehensive clinical research services, including central lab capabilities, to support pharmaceutical development worldwide.
• Barc Lab (Cerba Research): Barc Lab, part of Cerba Research, contributes through its extensive global network of central labs, offering a wide range of testing capabilities across various therapeutic areas.
• Bioscientia (Sonic Healthcare): Bioscientia, part of the larger Sonic Healthcare network, contributes to the central lab market primarily in Europe by providing specialized testing services and supporting clinical trials.
• Celerion: While focused primarily on early clinical research and bioanalytical services, Celerion contributes to the market by offering specialized laboratory testing and clinical pharmacology services that are crucial during the early phases of drug development.
• CIRION BioPharma Research: CIRION specializes in bioanalytical services, including immunochemistry and molecular biology testing, primarily supporting early-stage clinical trials. They offer specialized, high-quality laboratory services that help clients meet stringent regulatory requirements for drug development.
• Clinical Reference Laboratory (CRL): Primarily known for high-volume testing, CRL contributes to the central lab market through scalable testing services, often supporting large-scale screening programs or specific clinical trial needs.
• Lab Corp: A dominant player in the diagnostics and drug development market, LabCorp (through its Covance division) offers comprehensive central laboratory services globally.
• Eurofins Central Laboratory: Eurofins contributes to the market with a robust global network of state-of-the-art central labs, providing harmonized testing services to ensure consistent data delivery for international clinical trials.
• Frontage Laboratories, Inc.: Frontage offers a variety of services, including bioanalytical and central lab testing, focusing particularly on supporting drug development in both the US and China markets. Their expertise helps bridge the gap between regulatory requirements in different regions and speeds up the drug approval process.
• Icon Central Labs: Icon Central Labs is the dedicated central lab arm of the global CRO ICON, providing end-to-end laboratory services for clinical trials. They offer comprehensive lab management, logistics, and data handling that are seamlessly integrated into ICON's broader clinical trial services.
• INTERLAB Central Lab Services: Interlab contributes as a specialized central lab provider, offering a personalized approach to managing laboratory testing for clinical trials across Europe and other regions.
• LabConnect: LabConnect contributes as a leading provider of central lab support services, focusing on global sample management, procurement, and data integration for complex clinical trials.
• Medpace: Medpace is a scientifically-driven, global full-service CRO with extensive in-house central laboratory capabilities, contributing by integrating lab operations directly into their clinical its management processes.

Recent Developments

• In April 2026, Labcorp expanded its technology-first strategy by increasing the adoption of artificial intelligence (AI), robotics, and automation across laboratory operations to improve efficiency and support advanced diagnostic testing services. The initiative is aimed at reducing turnaround times while enhancing laboratory productivity and test accuracy.
• In July 2025, Labcorp raised its annual revenue outlook for its biopharma laboratory services business following strong demand for diagnostic testing and continued expansion of laboratory partnerships. The positive outlook reflects increasing outsourcing activities by pharmaceutical and biotechnology companies for clinical trial support services.

Segments Covered in the Report

By Product Type

• Genetic Services
• Biomarker Services
• Microbiology Services
• Special Chemistry Services
• Clinical Research & Trial Services
• Others

By End User

• Pharmaceutical Companies
• Biotechnology Companies
• Academic & Research Institutes
• Others

By Geography

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Malaysia
• Philippines
• Latin America
• Brazil
• Rest of Latin America
• Middle East & Africa (MEA)
• GCC
• North Africa
• South Africa
• Rest of the Middle East & Africa